Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 05 Jul 2023 for Aclaris Therapeutics, Inc.. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Gail Cawkwell: trading record in brief
This profile gathers the share dealings of Gail Cawkwell across 2 companies, led by Intercept Pharmaceuticals, Inc. and Aclaris Therapeutics, Inc. We count 7 filings; the first trade dates from 12 May 2021 and the latest from 1 July 2023.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The newest entry dates from 5 July 2023: an option exercise, in Aclaris Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Gail Cawkwell
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
15,000 sharesCommon StockSEC:0001209191-23-041060:0
320 shares@ US$15.804.3% of flowCommon StockSEC:0001104659-22-023838:0
6,600 shares0Common StockSEC:0001104659-22-009553:0
2,455 shares@ US$16.2965.5% of flowCommon StockSEC:0001104659-22-000909:0
319 shares@ US$19.049.8% of flowCommon StockSEC:0001104659-21-140028:0
319 shares@ US$15.287.7% of flowCommon StockSEC:0001104659-21-105301:0
319 shares@ US$17.758.7% of flowCommon StockSEC:0001104659-21-066143:0
7 of 7 declarations
